Inaxaplin | 2446816-88-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Inaxaplin
• 英文别名: 3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N-[(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide
• CAS: 2446816-88-0
• 化学式: C₂₁H₁₈F₃N₃O₃
• 分子量: 417.4
• InChiKey: CTXLPYZCBOVVQK-UZLBHIALSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  94.2
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20210275496A1

  公开（公告）日：2021-09-09

  This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.

  该申请描述了抑制APOL1和治疗APOL1介导疾病的方法，包括给予化合物I和/或其药学上可接受的盐。该申请还描述了包括化合物I和/或其药学上可接受的盐的制药组合物。
• [EN] SOLID FORMS OF APOL1 INHIBITOR AND USING THE SAME<br/>[FR] FORMES SOLIDES D'UN INHIBITEUR D'APOL1 ET UTILISATION DE CELLES-CI
  申请人：VERTEX PHARMA

  公开号：WO2021252863A1

  公开（公告）日：2021-12-16

  The disclosure provides novel solid state forms of Compound I selected from ethanol solvate Form A, ethanol solvate Form B, citric acid cocrystal Form A, and Form B, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease. (I).

  该披露提供了选择自乙醇溶剂结晶型A、乙醇溶剂结晶型B、柠檬酸共晶型A和型B的化合物I的新型固态形式，包括包含这些形式的组合物，以及制备和使用这些形式的方法，包括在治疗APOL1介导的肾脏疾病中的用途。
• INHIBITORS OF APOL1 AND METHODS OF USING SAME
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3897833A1

  公开（公告）日：2021-10-27
• [EN] INHIBITORS OF APOL1 AND METHODS OF USING SAME<br/>[FR] INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：VERTEX PHARMA

  公开号：WO2020131807A1

  公开（公告）日：2020-06-25

  The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
• [EN] METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSIS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA GLOMÉRULOSCLÉROSE SEGMENTAIRE ET FOCALE DÉPENDANTE DE L'APOL -1
  申请人：VERTEX PHARMA

  公开号：WO2021178768A1

  公开（公告）日：2021-09-10

  This application describes methods of inhibiting APOL1 and treating APOL1-mediated diseases comprising administering Compound I and/or a pharmaceutically acceptable salt thereof. Compound I The application also describes pharmaceutical compositions comprising Compound I and/or a pharmaceutically acceptable salt thereof.